focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,812.50
Bid: 1,700.00
Ask: 1,820.00
Change: 0.00 (0.00%)
Spread: 120.00 (7.059%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET MIDDAY: FTSE 100 rises as Lloyds brightens bank sector

Wed, 28th Apr 2021 12:05

(Alliance News) - London stocks sustained moderate gains on Wednesday morning, with banks helping to prop up the FTSE 100 ahead of the latest US interest rate decision after the European close.

As well as the US Federal Reserve's policy announcement due later, focus also is on results from New York-listed tech stocks Apple and Facebook.

The blue-chip FTSE 100 index was up 21.89 points, or 0.3%, at 6,966.86 midday Wednesday. The mid-cap FTSE 250 index was up 99.83 points, or 0.5%, at 22,532.91. The AIM All-Share index was down 0.3% at 1,272.55.

The Cboe UK 100 index was up 0.5% at 693.21. The Cboe 250 was up 0.3% at 20,121.44, and the Cboe Small Companies up flat at 14519.66.

In mainland Europe, the CAC 40 in Paris was up 0.5%, while the DAX 30 in Frankfurt was up 0.4% on Wednesday.

Joshua Mahony, senior market analyst at IG, remarked that markets were posting "tentative gains" on Wednesday.

"Markets are waiting patiently for the latest update from the Federal Reserve today, although they could be disappointed. Despite a resurgence in jobs and inflation data, we are unlikely to see Powell lay the groundwork for any tapering in asset purchases today," said Mahony.

The Fed announces its latest monetary policy decision at 1900 BST, with a press conference with Chair Jerome Powell at 1930 BST.

The dollar climbed ahead of the US interest rate decision.

Sterling was quoted at USD1.3881 midday Wednesday, lower than USD1.3915 at the London equities close on Tuesday. The euro traded at USD1.2072, soft on USD1.2085 late Tuesday. Against the yen, the dollar was quoted at JPY108.92, up from JPY108.50.

However, stocks in New York were set for a largely lower open. The Dow Jones was called down 0.1% and the Nasdaq Composite was seen 0.2% lower, but the S&P 500 was set for a 0.1% rise.

Likely to weigh on the Nasdaq at the open are shares in Microsoft, trading 2.2% lower pre-market despite the software firm reporting quarterly profit growth. For its financial third quarter ended March 31, revenue was USD41.7 billion, up 19% from USD35.02 billion the year before and net income jumped 44% to USD15.46 billion from USD10.75 billion.

"One-off tax and currency advantages have boosted Microsoft's third quarter numbers, and as a result the market isn't being quite as welcoming of expectation-beating numbers as you might expect. That is the danger of trading on the kind of valuation Microsoft enjoys, 32.8 times next year's earnings, disappoint even a little and the market will be unforgiving," said Nicholas Hyett, equity analyst at Hargreaves Lansdown.

More positively, Alphabet shares jumped 5.1% pre-market on sharp growth in earnings and revenue for the first quarter of 2021, driven by a rise in online consumer activity and advertiser revenue. For the three months to the end of March, the Google parent posted net income of USD17.93 billion, more than doubled from USD6.84 billion the same period the year before.

Focus switches to the next raft of US tech earnings, with reports from iPhone maker Apple and social media behemoth Facebook after the New York market close.

In London, a strong first quarter showing from high street lender Lloyds was helping the boost other UK banks. NatWest shares rose 2.0% and Barclays was up 1.2%.

Lloyds topped the FTSE 100 at midday, shares up 4.4%, as profit shot up in the first quarter of 2021 in outgoing Chief Executive Antonio Horta-Osorio's last set of results at the bank.

Pretax profit for the three months to the end of March surged to GBP1.90 billion from just GBP74 million a year ago, aided by a net impairment credit of GBP323 million, versus a charge of GBP1.43 billion a year ago.

Given the "solid performance" in the first quarter of 2021, Lloyds enhanced its guidance for 2020. Its net interest margin is now expected to be in excess of 245 basis points, after posting 249 basis points for the first quarter, and operating costs to be reduced to GBP7.5 billion.

HSBC Wealth & Personal Banking head Charlie Nunn will become the new Lloyds CEO on August 16. Lloyds Chief Financial Officer William Chalmers will be interim-CEO after Horta-Osorio departs and before Nunn comes in.

Horta-Osorio is heading to Credit Suisse to be its new chair - joining at a rocky time for the Swiss bank after it last week swung to a first quarter loss due to the implosion of US hedge fund Archegos.

The FTSE 100 also was supported by advertising and marketing firm WPP, shares up 3.6% at midday. In the first quarter of 2021, revenue rose 1.8% annually to GBP2.90 billion. On a like-for-like basis, WPP's first quarter revenue was 6.3% higher.

At the bottom of the FTSE 100 was precious metals miner Fresnillo, down 3.1% after a slightly mixed first quarter.

Gold output in the first quarter of 2021 rose 16% annually to 228,193 ounces. This represented a 5.9% quarter-on-quarter hike from 215,581 ounces in the fourth quarter of 2020.

Total silver output, however, fell 4.5% annually to 12.6 million ounces from 13.2 million and 2.4% on a quarterly basis from 13.0 million.

Gold was quoted at USD1,767.66 an ounce on Wednesday, lower than USD1,780.50 on Tuesday. Brent oil was trading at USD66.43 a barrel, up from USD66.11 late Tuesday.

J Sainsbury fell 2.6% as the grocer was pulled to a full-year loss on virus-related costs.

In the year ended March 8, the London-based grocer's revenue rose 0.2% to GBP29.04 billion, from GBP28.99 billion. It swung to a pretax loss of GBP261 million from the prior year's GBP255 million profit.

Underlying pretax profit fell 39% to GBP356 million, topping consensus of GBP338 million as well as the company's own forecast of GBP330 million. Profit was hit by GBP485 million of direct Covid-19 costs, offsetting a strong sales performance excluding fuel. Fuel sales were hurt by reduced demand during lockdown and the impact of lower crude oil prices on the petrol sales price.

Reckitt Benckiser slipped 2.2% despite reporting like-for-like revenue growth in the first quarter, leaving its full-year guidance unchanged.

The Slough, Berkshire-based consumer health and hygiene products company's total net revenue for the first quarter of 2021 grew 4.1% on a like-for-like basis, though fell 1.1% on a reported basis. Demand for Lysol and Dettol continues to be strong, the company said, amid "ongoing, elevated demand" for its disinfection products overall.

Reporting at midday, pharmaceutical firm GlaxoSmithKline confirmed its earlier financial guidance for 2021 and said the spin-off of its consumer arm is on track for 2022. In the first quarter, sales totalled GBP7.4 billion, up 18% or up 15% at constant exchange rates.

Glaxo shares were up 1.3% following the announcement.

In the FTSE 250, Grafton Group jumped 9.7%. The Dublin-based building materials distributor and DIY retailer said its first quarter revenue rose by a third.

Grafton recorded revenue of GBP846.8 million between January 1 and April 18, an increase of 33% on the same period last year and an 8.3% rise compared to 2019. The revenue gains were driven by the Retailing segment, with revenue more than doubling from a year prior and up 70% from 2019.

Travis Perkins fell 8.3% after the builders' merchant completed the demerger of its DIY retailing business, with Wickes Group making its London Main Market debut. Wickes was trading at 270.70 pence per share, giving it a value just over GBP680 million.

The Northampton-based firm added it will implement a share consolidation to keep its stock price close to pre-demerger levels. The ratio for the share consolidation will depend on its stock price at the close of trading on Wednesday.

By Lucy Heming; lucyheming@alliancenews.com

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
13 Feb 2024 12:06

LONDON MARKET MIDDAY: Stocks fall but pound up before US data

(Alliance News) - Stock prices in London were on the decline on Tuesday afternoon, with sentiment tetchy ahead of a US inflation report later.

Read more
13 Feb 2024 09:45

Citi ups recommendation on GSK to 'buy'

(Sharecast News) - Citi has upgraded its rating on vaccines and drugs blue chip GSK to 'buy' while also boosting its earnings estimates.

Read more
13 Feb 2024 09:32

LONDON BROKER RATINGS: Citi lifts GSK; Shore likes XPS Pensions

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Monday:

Read more
13 Feb 2024 07:45

LONDON BRIEFING: "Record" Tui quarter; Ultimate Products eyes payouts

(Alliance News) - London's FTSE 100 is to open ever-so-slightly lower on Tuesday, with trade set to be nervy ahead of the afternoon's US inflation data.

Read more
12 Feb 2024 17:11

London close: Stocks finish higher after very quiet Monday

(Sharecast News) - London markets managed modest gains by the close of a subdued trading session on Monday, with no significant corporate or economic catalysts driving movements.

Read more
12 Feb 2024 12:04

LONDON MARKET MIDDAY: FTSE 100 underperforms as European peers rise

(Alliance News) - London's FTSE 100 underwhelmed on Monday, with some of its largest constituents pulling it lower, while indices in Europe were on the up on favourable comments on interest rate cuts by a European Central Bank official.

Read more
12 Feb 2024 08:35

TOP NEWS: GSK's bepirovirsen receives US FDA fast track designation

(Alliance News) - GSK PLC on Monday said that the US health watchdog granted fast track designation for its bepirovirsen treatment for chronic hepatitis B.

Read more
12 Feb 2024 07:50

LONDON BRIEFING: Tritax Big Box, UK Commercial Property agree merger

(Alliance News) - Equities in London are called to open higher on Monday, with inflation readings from the US and UK on the horizon, which could drive equity market sentiment during the remainder of the week.

Read more
12 Feb 2024 07:21

GSK gets FDA fast track for chronic hepatitis B treatment

(Sharecast News) - GSK announced on Monday that bepirovirsen, an investigational antisense oligonucleotide (ASO) aimed at treating chronic hepatitis B (CHB), had been granted fast track designation by the US Food and Drug Administration (FDA).

Read more
9 Feb 2024 09:15

LONDON BROKER RATINGS: Deutsche Bank cuts AstraZeneca to 'sell'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
6 Feb 2024 08:51

TOP NEWS: GSK reports positive news on trio of high profile products

(Alliance News) - GSK PLC on Tuesday delivered a triple dose of positive updates on some of its leading products, Arexvy, Shingrix and Blencep.

Read more
6 Feb 2024 07:47

LONDON BRIEFING: BP promises buyback despite drop in profit

(Alliance News) - Stocks in London are called to open higher, ahead of a slew of construction purchasing managers' index readings from the eurozone, the UK and Germany.

Read more
6 Feb 2024 07:23

GSK reports positive myeloma trial results, progresses vaccine applications

(Sharecast News) - GSK reported progress in its trial of a myeloma treatment on Tuesday, as well as regulatory progress around its shingles vaccine in China and its RSV vaccine in the United States.

Read more
1 Feb 2024 09:27

TOP NEWS: GSK maintains "vigorous" defence after settling Zantac case

(Alliance News) - GSK PLC on Thursday insisted upon its scientific integrity, after reaching another settlement in ongoing litigation over alleged links between its heartburn drug and cancer.

Read more
1 Feb 2024 09:11

GSK settles Zantac case in California without admitting liability

(Sharecast News) - GSK announced on Thursday that it had reached a confidential settlement to effectively resolve the legal case over Zantac filed in a California state court.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.